Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption

Pharmaceutical Research

Volumn 16, Issue 6, 1999, Pages 882-888

  Balon, K ^a   Riebesehl, B U ^a   Muller B W ^b  

^a LILLY DEUTSCHLAND GMBH   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

Author keywords

Absorption; Liposomes; Octanol; Partitioning; Phospholipids; Solubility

Indexed keywords

ACETYLSALICYLIC ACID; ACICLOVIR; ALLOPURINOL; AMILORIDE; ATENOLOL; DICLOFENAC; FAMOTIDINE; FLUOXETINE; FUROSEMIDE; IBUPROFEN; LIPOSOME; MICONAZOLE; MOXONIDINE; NIZATIDINE; OLANZAPINE; PAROMOMYCIN; PROPRANOLOL; RIFABUTIN; TERBINAFINE; XIPAMIDE; ZIDOVUDINE; ZOPICLONE;

ARTICLE; DRUG ABSORPTION; DRUG SOLUBILITY; DRUG STRUCTURE; INTESTINE ABSORPTION; PARTITION COEFFICIENT; PH MEASUREMENT; PRIORITY JOURNAL; TITRIMETRY;

HUMANS; INTESTINAL ABSORPTION; LIPOSOMES; OCTANOLS; SOLUBILITY;

EID: 0033013540     PISSN: 07248741     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1018882221008     Document Type: Article

References (34)

1. 1. C. A. Lipinski, F. Lombardo, B. W. Dominy, and P. J. Feeney. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Del. Rev. 23:3-25 (1997).
2. 2. S. Yee. In vitro permeability across Caco-2 cells (colonic) can predict in vivo (small intestinal) absorption in man - fact or myth. Pharm. Res. 14:763-766 (1997).
3. 3. K. J. Schaper. Absorption of ionizable drugs: nonlinear dependence on logP, pKa and pH-quantitative relationships. Quant.Struct.-Act.Relat. 1:13-27 (1982).
4. 4. P. A. Shore, B. B. Brodie, and C. A. M. Hogben. The gastric secretion of drugs: A pH partition hypothesis. J. Pharmacol. Exp. Ther. 119:361-369 (1957).
5. 5. C. J. Alcorn, R. J. Simpson, D. E. Leahy, and T. J. Peters. Partition and distribution coefficients of solutes and drugs in brush border membrane vesicles. Biochem. Pharmacol. 45:1775-1782 (1993).
6. 6. F. Barbato, M. I. la Rotonda, and F. Quaglia. Interactions of nonsteroidal antiinflammatory drugs with phospholipids: comparison between octanol/buffer partition coefficients and Chromatographic indexes on immobilized artificial membranes. J. Pharm. Sci. 86:225-229 (1997).
7. 7. H.-Y. Cheng, C. S. Randall, W. W. Holl, P. P. Constantinides, T.-L. Yue, and G. Z. Feuerstein. Carvedilol-liposome interaction: evidence for strong association with the hydrophobic region of the lipid bilayers. Biochim. Biophys. Acta 1284:20-28 (1996).
8. 8. G. V. Betageri, Y. Theriault, and J. A. Rogers. NMR Study of the interaction of beta-blockers with sonicated dimyritoylphosphatidylcholine liposomes in the presence of praseodymium cation. Membrane Biochem. 8:197-206 (1989).
9. 9. F. A. P. C. Gobas, J. M. Lahittete, G. Garofalo, W. Y. Shiu, and D. MacKay. A novel method for measuring membrane-water partition coefficients of hydrophobic organic chemicals: comparison with I-octanol-water partitioning. J. Pharm. Sci. 77:265-272 (1988).
10. 10. A. Avdeef, K. J. Box, J. E. A. Comer, C. Hibbert, and K. Y. Tam. pH-metric logP 10: Determination of vesicle membrane-water partition coefficients of ionisable drugs. Pharm. Res. 15:209-215 (1998).
11. 11. A. Avdeef. pH-Metric logP. Part I : Difference plots for determining ion-pair octanol-water partition coefficients of multiprotic substances. Quant. Struct.-Act. Relat. 11:510-517 (1992).
12. 12. A. Avdeef. pH-metric IogP-2. Refinement of partition coefficients and ionisation constants of multiprotic substances. J. Pharm. Sci. 82:183-190 (1993).
13. 13. P. Finholt and S. Solvang. Dissolution kinetics of drugs in human gastric juice - the role of surface tension. J. Pharm. Sci. 57:1322-1326 (1968).
14. 14. L. S. C. Wan and P. F. S. Lee. CMC of Polysorbates. J. Pharm. Sci. 63:136-137 (1974).
15. 15. G. Camenisch, G. Folkers, and H. van de Waterbeemd. Review of passive drug absorption models: historical background, recent developments and limitations. Pharm. Acta Helv. 71:309-327 (1996).
16. 16. J. B. Dressman,G. L. Amidon, and D. Fleisher. Absorption potential: Estimating the fraction absorbed for orally administered compounds. J. Pharm. Sci. 74:588-589 (1985).
17. 17. J. B. Dressman, and V. A. Gray. Change of pH intestinal fluid. Pharmacopeial Forum 22:1943-1945 (1996).
18. 18. H. Lennernäs. Does fluid flow across the intestinal mucosa affect quantitative oral drug absoiption? Is it time for a reevaluation? Pharm. Res. 12:1573-1582 (1995).
19. 19. K. Hartke (ed). DAB10 Kommentar Wiss. Verl.-Ges. Stuttgart, 1991.
20. 20. P. de Miranda, and M. R. Blum. Pharmacokinetics of acyclovir after intravenous and oral administration. J. Antimicrob. Chemother. 12 Suppl. B:29-37 (1983).
21. 21. H. Breithaupt and M. Tittel. Kinetics of allopurinol after single intravenous and oral doses. Eur. J. Clin. Pharmacol. 22:77-84 (1982).
22. 22. F. von Bruchhausen (ed.). Hagers Handbuch der pharmazeutischen Praxis, 5. Aufl., Springer Verlag Berlin, 1993.
23. 23. W. F. Frishman. Atenolol and timolol, two new systemic b-adrenoceptor antagonists. N. Engl. J. Med. 306:1456-1462 (1982).
24. 24. J. E. F. Reynolds, (ed), Martindale, The Extra Pharmacopoeia, 31st Edition, The Royal Pharmaceutical Society London, 1996.
25. 25. K. Lauritsen, L. S. Laursen, and J. Rask-Madsen. Clinical Pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part I). Clin. Pharmacokinet. 19:11-31 (1990).
26. 26. L. Lemberger, R. F. Bergstrom, R. L. Wollen, N. A. Farid, G. G. Enas, and G. R. Aronoff. Fluoxetine: Clinical pharmacology and physiological disposition. J. Clin. Psychiatry 46:14-19 (1985).
27. 27. R. F. N. Mills, S. S. Adams, E. E. Cliffe et al. The metabolism of ibuprofen. Xenobiotica 3:589-598 (1973a).
28. 28. R. A.Theodor, H.-J. Weimann, W. Weber et al. Absolute bioavailabilily of moxonidine. Eur. J. Drug Metah. Pharmacokinet. 16:153-159 (1991).
29. 29. B. Fulton, and K. L. Goa. Olanzapine A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53:281-298 (1997).
30. 30. P. A. Routledge and D. G. Shand, Clinical pharmacokinetics of propranolol. Clin. Pharmacokinet. 4:73-90 (1979).
31. 31. M. H. Skinner, and T, F Blaschke. Clinical pharmacokinetics of rifabutin. Cin. Pharmacokinet. 28:115-125 (1995).
32. 32. J. C. Jensen. Clinical pharmacokinetics of terbinafine. Clin. Exp. Dermatol. 14:1 10-113 (1989).
33. 33. H. D. Langtry and D. M. Campoli-Richards. Zidovudin. Drugs 37:407-450 (1989).
34. 34. A. N. Wadworth and D. McTavish. Zopiclone A review of its pharmacological properties and therapeutic efficacy. Drugs & Aging 3:441-459 (1993).